Neurocrine Biosciences (NBIX) Tax Provisions (2019 - 2026)

Neurocrine Biosciences (NBIX) has reported Tax Provisions for 8 consecutive years, with $17.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Tax Provisions fell 65.77% year-over-year to $17.8 million; the trailing twelve-month figure through Jun 2026 stood at $234.7 million (up 31.26% YoY), and the FY2025 full-year result was $226.8 million, up 56.74% from the prior year.
• Tax Provisions eased to $17.8 million in Q2 2026 per NBIX's latest filing, from $48.9 million in the prior quarter.
• Across five years, Tax Provisions topped out at $85.7 million in Q4 2025 and bottomed at -$26.7 million in Q1 2023.
• Historically, Tax Provisions has averaged $32.2 million across 5 years, with a median of $31.0 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Tax Provisions tumbled 456.0% in 2023, then surged 619.12% in 2026.
• Over 5 years, Tax Provisions stood at $28.9 million in 2022, then surged by 74.74% to $50.5 million in 2023, then rose by 17.82% to $59.5 million in 2024, then soared by 44.03% to $85.7 million in 2025, then tumbled by 79.23% to $17.8 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $17.8 million, $48.9 million, and $85.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.